Structured evidence table for Sulforaphane Oxidative Stress Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Sulforaphane Oxidative Stress Randomized Trial | In whole blood, Kelch-like ECH-associating protein 1 (KEAP1) and catalase (CAT) mRNA levels were significantly reduced in iSLE and qSLE. | 4 | Liu L (2026) | Oxidative Stress and NRF2-Mediated Redox Regulation in Incomplete Systemic Lupus Erythematosus and Systemic Lupus Erythematosus. |
| Sulforaphane Oxidative Stress Randomized Trial | In conclusion, in qSLE patients, oxidative stress is elevated, while antioxidant capacity is decreased. | 4 | Liu L (2026) | Oxidative Stress and NRF2-Mediated Redox Regulation in Incomplete Systemic Lupus Erythematosus and Systemic Lupus Erythematosus. |
| Sulforaphane Oxidative Stress Randomized Trial | To elucidate whether it is already present in early phases, we investigate oxidative stress-related genes in incomplete SLE (iSLE) and quiescent SLE (qSLE, inactive disease), as well as the effect of nuclear factor erythroid-derived 2-like 2 (NRF2) activators on NRF2-related genes in peripheral blood mononuclear cells (PBMCs) and HaCaT keratinocytes. | 4 | Liu L (2026) | Oxidative Stress and NRF2-Mediated Redox Regulation in Incomplete Systemic Lupus Erythematosus and Systemic Lupus Erythematosus. |
| Sulforaphane Oxidative Stress Randomized Trial | In total, 28 qSLE patients, 29 iSLE patients and 21 age- and sex-matched healthy controls (HCs) were included. | 4 | Liu L (2026) | Oxidative Stress and NRF2-Mediated Redox Regulation in Incomplete Systemic Lupus Erythematosus and Systemic Lupus Erythematosus. |
| Sulforaphane Oxidative Stress Randomized Trial | Sulforaphane Mitigates Oxidative Stress in Alzheimer's Disease (AD) through NRF2 Activation | 4 | Khan Wasi Uzzaman (2025) | Sulforaphane Mitigates Oxidative Stress in Alzheimer's Disease (AD) through NRF2 Activation |
Source documents